Improving Radiation Treatment for Pancreatic Cancer with Targeted Nanoparticles
Official title: In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy
Funded at University of Tx Md Anderson Can Ctr · NIH-11132625 · Data updated 2026-11-12
This work explores a new way to deliver tiny particles directly to pancreatic cancer cells, aiming to make radiation therapy more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 2, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $597,297 |
| NIH project number | 5R01CA274415-04 |
| Project ID | NIH-11132625 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational work is for patients with pancreatic cancer, particularly those who may benefit from intensified radiation therapy.
✕Less likely to help
Patients whose cancer does not respond to radiation therapy or those with other cancer types may not directly benefit from this specific approach.
What this research studies
Pancreatic cancer is very difficult to treat because tumors are often protected by a dense barrier. This project looks at a clever method where cancer cells are encouraged to create their own tiny gold particles right inside the tumor. These particles can then help radiation therapy work better by increasing the radiation dose specifically within the cancer cells, while hopefully sparing healthy tissues. This approach aims to get past the tumor's protective barrier without destroying it, which could lead to more powerful and precise treatments.
Why it matters
Potential benefit: If successful, this approach could make radiation therapy much more effective for pancreatic cancer patients, potentially leading to better outcomes.
How similar studies have gone: The concept of in situ biomineralization by cancer cells is a recently reported and novel strategy, building on existing knowledge of nanoparticle radiosensitization.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Sokolov, Konstantin V — University of Tx Md Anderson Can Ctr
- Study coordinator: Sokolov, Konstantin V
Related research
Other NIH-funded projects on the same topics.
-
In situ cancer cell mineralization to boost radiotherapy for pancreatic cancer
Aims to help pancreatic cancer patients by using tiny gold minerals made inside cancer cells to improve radiotherapy effectiveness while sparing healthy tissue.
-
Real-time MRI-guided adaptive radiation for inoperable pancreatic cancer
This approach uses real-time MRI to guide high-dose, focused radiation for people with pancreatic tumors that cannot be removed by surgery.
-
Targeted radiotherapy for pancreatic cancer
This study is looking at a new treatment for advanced pancreatic cancer by using a special antibody called TAB004 that helps deliver radiation directly to the cancer cells, making the treatment more effective for patients.
-
Using real-time MRI to improve radiation therapy for pancreatic cancer
This study is looking at a new way to make radiation therapy better for people with pancreatic cancer that can't be surgically removed, using special MRI technology to track tumor movement and deliver radiation more accurately, which could help improve treatment results while protecting healthy tissue.
-
Using gold nanoparticles to improve radiation treatment for pancreatic cancer
This study is testing a new way to make radiation therapy work better for people with pancreatic cancer by using tiny gold particles that can be delivered right to the cancer cells, helping to target the tumor more effectively while protecting healthy tissue.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.